Association between ALK tyrosine kinase inhibitor and the risk of interstitial lung disease and pneumonitis in non-small cell lung cancer patients: a systematic review

BMC Cancer. 2026 Jan 24. doi: 10.1186/s12885-026-15612-3. Online ahead of print.
No abstract available

Keywords: Anaplastic lymphoma kinase tyrosine kinase inhibitor; Interstitial lung disease; Non-small cell lung cancer; Pneumonitis.

Publication types

  • Systematic Review